GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

Affiliations

• 1 Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, 42415, Republic of Korea.
• 2 Department of Laboratory Medicine, College of Medicine, Yeungnam University, Yeungnam University Medical Center, Daegu, 42415, Republic of Korea.
• 3 Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea. hongnam.kim@kist.re.kr.
• 4 Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Seoul, 02792, Republic of Korea. hongnam.kim@kist.re.kr.
• 5 Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea. hidongha@catholic.ac.kr.
• 6 Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. wonhwalee@kribb.re.kr.